サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1247465

血液腫瘍検査の世界市場-2023-2030

Global Hemato Oncology Testing Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
血液腫瘍検査の世界市場-2023-2030
出版日: 2023年03月28日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

世界の血液腫瘍検査市場は、2022年に2億8,000万米ドルに達し、2030年には最大6億2,000万米ドルに達することで有利な成長を遂げると予測されています。同市場は予測期間（2023-2030年）にCAGR 4.8%で成長しています。

血液腫瘍学は、血液を研究する血液学と、がんを研究する腫瘍学という2つの医学分野を統合したものです。血液腫瘍医は、血液がんや血液関連疾患の診断、治療、予防のためのトレーニングを受けています。血液腫瘍学の分野は、血液および関連するがんの治療を扱っています。

市場力学

医薬品診断・サービスの技術的進歩

市場への進歩や新しい技術的に高度な製品の導入が進んでいることが、世界のヘマトオンコロジー検査市場の成長を後押ししています。例えば、2022年8月、Thermo Fisher Scientific社は、精密腫瘍バイオマーカー検査へのアクセスを拡大するために、CE-IVD（IVDD）次世代シーケンス検査および分析ソフトウェアを発表しました。同様に、2022年6月、Burning Rock Biotech Limitedは、OverC multi-cancer estimation blood testのCEマーキングを付与されました。OverCマルチがん推定血液検査は、次世代シーケンサー（NGS）をベースとした定性的な体外診断装置です。同様に、2021年11月、SAN DIEGOとGenetic Allianceは、遺伝性疾患に罹患した世界中の数万人の個人に全ゲノムシーケンスアクセス（WGS）を提供することを目的としたiHope Genetic Healthプログラムを立ち上げました。

個別化医療に関する意識の高まりが、市場に有利な成長機会をもたらしています。

個別化医療とは、個人の遺伝的プロファイルを利用して、疾患の予防、診断、治療のための意思決定を行う医療行為で、急速に普及しています。患者の遺伝子プロファイルを知ることで、医師は最も正確な薬や治療法を選択し、適切な量やレジメンを使用して投与することができます。例えば、2021年1月、FDAは、個別化医療の役割が拡大し続けていることから、新規治療法の設計に関する知識を医師に提供することに関与することを宣言しました。さらに、欧州がん患者連合（ECPC）は、11月中に最初の個別化医療啓発月間を主導し、ECPCは、個別化医療啓発月間と呼ばれる1ヶ月間の提唱キャンペーンで、がん分子検査へのアクセスの意義を推進しました：がんコードを解読する」と題したキャンペーンを実施しました。

目次

第1章 調査手法とスコープ

  • 調査手法
  • 調査目的および調査範囲について

第2章 定義と概要

第3章 エグゼクティブサマリー

  • 製品・サービスのタイプ別スニペット
  • 技術別スニペット
  • がんの種類別スニペット
  • エンドユーザー別スニペット
  • 地域別スニペット

第4章 ダイナミックス

  • インパクトのあるファクター
    • 促進要因
      • 薬物診断とサービスの技術的進歩
      • 世界的に増加する血液がんの有病率
    • 抑制要因
      • 不利で不確実な償還シナリオ
    • 機会
    • 影響度分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格アナリシス
  • レギュラトリー・アナリシス

第6章 COVID-19の分析

  • COVID-19の解析について
    • COVID-19シナリオ前
    • 現在のCOVID-19シナリオ
    • ポストCOVID-19またはフューチャーシナリオ
  • COVIDの中での価格ダイナミクス-19
  • 需給スペクトル
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的な取り組み
  • 結論

第7章 製品・サービスタイプ別

  • 楽器
  • 試薬・消耗品
  • サービス内容

第8章 テクノロジー別

  • PCR（ポリメラーゼ・チェーン・リアクション）
  • IHC（免疫組織化学）
  • NGS（次世代シーケンサー）
  • 細胞遺伝学
  • その他

第9章 がんタイプ別

  • 白血病
    • 急性骨髄性白血病（Acute Myeloid Leukemia
    • 急性リンパ性白血病（Acute Lymphocytic Leukemia
    • その他
  • リンパ腫
  • 多発性骨髄腫
  • その他

第10章 エンドユーザー別

  • クリニカルラボラトリーズ
  • 病院
  • 学術・研究機関など
  • その他

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • ロシア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第12章 競合情勢

  • 競合シナリオ
  • 市況分析・シェア分析
  • M&A分析

第13章 企業プロファイル

  • F. Hoffman-La Roche Ltd.
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な展開
  • Abbott Laboratories
  • Qiagen N.V.
  • Thermo Fisher Scientific, Inc.
  • Illumina, Inc.
  • Bio-Rad Laboratories, Inc.
  • ICON PLC
  • Archerdx, Inc.
  • Invivoscribe, Inc.
  • Adaptive Biotechnologies

第14章 付録

目次
Product Code: CD1347

Market Overview

The global hemato oncology Testing market reached US$ 280 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 620 million by 2030. The market is growing at a CAGR of 4.8% during the forecast period (2023-2030).

Hematologic oncology integrates two fields of medicine: hematology, the study of the blood, and oncology, the study of cancer. Hematologic oncologists are trained in diagnosing, treating, and preventing blood cancers and blood-related disorders. The field of haemato-oncology deals with the treatment of blood and related cancers.

Market Dynamics

Technological advancements in drug diagnosis and services

The growing advancements and new technologically advanced product introductions into the market are boosting the global hemato oncology testing market growth. For instance, in August 2022, Thermo Fisher Scientific introduced CE-IVD (IVDD) next-generation sequencing test and analysis software to extend access to precision oncology biomarker testing. Likewise, in June 2022, Burning Rock Biotech Limited was granted a CE marking for its OverC multi-cancer estimation blood test. OverC Multi-Cancer Detection Blood Test is a qualitative next-generation sequencing (NGS)-based in vitro diagnostic device. Similarly, in November 2021, SAN DIEGO and Genetic Alliance created the iHope Genetic Health program targeted at delivering whole-genome sequencing access (WGS) to tens of thousands of individuals all over the globe affected by genetic disease.

Growing awareness regarding personalized medicines is presenting the market with lucrative growth opportunities.

Personalized medicine is a blossoming practice of medicine that employs an individual's genetic profile to direct decisions formed for the prevention, diagnosis, and treatment of the disorder. Knowledge of a patient's genetic profile can aid physicians to choose the most accurate medication or therapy and administer it utilizing the appropriate dose or regimen. The growing awareness and efforts to implement personalized medicine are providing the market with very lucrative growth opportunities For instance, in January 2021, the FDA declared its involvement in providing physicians with knowledge on the designing of novel therapies as the role of personalized medicine keeps on expanding. Furthermore, the European Cancer Patient Coalition (ECPC) lead the first Personalized Medicine Awareness Month throughout November, the ECPC promoted the significance of access to cancer molecular testing during a month-long advocacy campaign called, Personalized Medicine Awareness Month: Cracking the Cancer Code.

Segment Analysis

The global hemato oncology testing market is segmented based on Product & Services, Cancer Type, Technology, and region.

Owing to growing new technological advancements, product launches, and recent development

The increasing market developments such as collaborations, and product launches among others are boosting the services segment growth during the forecast period. For instance, in August 2020 Thermo Fisher Scientific introduced hematology-oncology assays for the Ion Torrent Genexus System. Also, in May 2022, the Qatar Foundation (QF) division of the Qatar Genome Program (QGP), and Thermo Fisher Scientific partnered for the advancement of genomic research and clinical applications of predictive genomics in Qatar as a step in the direction of expanding the benefits of precision medicine all over the Arab populations worldwide. Similarly, in August 2022, Mount Sinai Health System and the Icahn School of Medicine introduced a new human genome sequencing research project known as the Mount Sinai Million Health Discoveries Program with the Regeneron Genetics Center (RGC). Thus, the mentioned data indicates that the services segment will dominate the global hemato-oncology testing market throughout the forecast period.

Geographical Penetration

The strong presence of major players and increased awareness about the use of eco-friendly products

North America dominates the global hemato oncology testing market during the forecast period, owing to the growing cases of leukemia, better reimbursement policies, and the presence of key market players holding the majority of the market in this region. For instance, according to the Canada Cancer Society report that there were over 6,700 Canadians diagnosed with leukemia, of which around 4,000 were men and about 2,700 were women in 2021. Also, the American Cancer Society documented that approximately 60,650 new cases of leukemia and 20,050 new cases of acute myeloid leukemia (AML) were diagnosed in the United States in 2022. Also, acute myeloid leukemia (AML) made up only about 1% of all cancers. Furthermore, Abbott Laboratories, Thermofisher Scientific, and Illumina are among the key market players holding the majority of market share based in the North American region ensuring the dominance of the region over the global market.

Competitive Landscape

The major global players include F. Hoffman-La Roche Ltd., Abbott Laboratories, Qiagen N.V., Thermo Fisher Scientific, Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., ICON PLC, Archerdx, Inc., Invivoscribe, Inc., and Adaptive Biotechnologies.

COVID-19 Impact Analysis

By Type of Product & Service

  • Instruments
  • Reagents & Consumables
  • Services

By Technology

  • PCR (Polymerase Chain Reaction)
  • IHC (immunohistochemical)
  • NGS (Next-Generation Sequencing)
  • Cytogenetics
  • Others

By Cancer Type

  • Leukemia
    • Acute Myeloid Leukemia
    • Acute Lymphocytic Leukemia
    • Others
  • Lymphoma
  • Multiple myelomas
  • Others

By End-user

  • Clinical Laboratories
  • Hospitals
  • Academic & Research Institutes
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Russia
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • In 2022, the US FDA granted approval to F. Hoffmann-La Roche Ltd. (Switzerland) for its cobras EZH2 mutation test as a companion diagnostic for patients with follicular lymphoma.
  • In 2020, F. Hoffmann-La Roche Ltd. (Switzerland) and Illumina Inc. (US) formed a 15-year non-exclusive collaboration with Illumina to extend the adoption of NGS-based testing in oncology.
  • In 2021, QIAGEN N.V. (Germany) and Denovo Biopharma LLC (US) formed a partnership to design a blood-based companion diagnostic (CDx) test for the treatment of diffuse large B-cell lymphoma (DLBCL), one of the most typical lymphoid cancers.

Why Purchase the Report?

  • To visualize the global Hemato Oncology Testing- market segmentation based on product, application and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of Hemato Oncology Testing market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global Hemato Oncology Testing market report would provide approximately 69 tables, 71 figures and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type of Products & Services
  • 3.2. Snippet by Technology
  • 3.3. Snippet by Type of cancer
  • 3.4. Snippet by End-user
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Technological Advancements In Drug Diagnosis And Services
      • 4.1.1.2. Increasing Prevalence of Hematologic Cancer Globally
      • 4.1.1.3. XX
    • 4.1.2. Restraints
      • 4.1.2.1. Unfavorable And Uncertain Reimbursement Scenario
      • 4.1.2.2. XX
    • 4.1.3. Opportunity
      • 4.1.3.1. XX
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Before COVID-19 Scenario
    • 6.1.2. Present COVID-19 Scenario
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type of Product & Service

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type of Product & Service
    • 7.1.2. Market Attractiveness Index, By Type of Product & Service
  • 7.2. Instruments
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Reagents & Consumables
  • 7.4. Services

8. By Technology

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 8.1.2. Market Attractiveness Index, By Technology
  • 8.2. PCR (Polymerase Chain Reaction) *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. IHC (immunohistochemical)
  • 8.4. NGS (Next-Generation Sequencing)
  • 8.5. Cytogenetics
  • 8.6. Others

9. By Cancer Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 9.1.2. Market Attractiveness Index, By Cancer Type
  • 9.2. Leukemia*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 9.2.3. Acute Myeloid Leukemia
    • 9.2.4. Acute Lymphocytic Leukemia
    • 9.2.5. Others
  • 9.3. Lymphoma
  • 9.4. Multiple myelomas
  • 9.5. Others

10. By End-user

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 10.1.2. Market Attractiveness Index, By End-user
  • 10.2. Clinical Laboratories*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Hospitals
  • 10.4. Academic & Research Institutes
  • 10.5. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type of Product & Service
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Caner Type
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Caner Type
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.6.1. Germany
      • 11.3.6.2. UK
      • 11.3.6.3. France
      • 11.3.6.4. Italy
      • 11.3.6.5. Russia
      • 11.3.6.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Caner Type
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.6.1. Brazil
      • 11.4.6.2. Argentina
      • 11.4.6.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Caner Type
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.6.1. China
      • 11.5.6.2. India
      • 11.5.6.3. Japan
      • 11.5.6.4. Australia
      • 11.5.6.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Caner Type
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. F. Hoffman-La Roche Ltd.*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Abbott Laboratories
  • 13.3. Qiagen N.V.
  • 13.4. Thermo Fisher Scientific, Inc.
  • 13.5. Illumina, Inc.
  • 13.6. Bio-Rad Laboratories, Inc.
  • 13.7. ICON PLC
  • 13.8. Archerdx, Inc.
  • 13.9. Invivoscribe, Inc.
  • 13.10. Adaptive Biotechnologies

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us